Translational findings for odronextamab: From preclinical research to a first‐in‐human study in patients with CD20+ B‐cell malignancies-Reference-Cited by-同舟云学术

Translational findings for odronextamab: From preclinical research to a first‐in‐human study in patients with CD20+ B‐cell malignancies

Published:2022-01-07 Issue:4 Volume:15 Page:954-966
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical Translational Sci

Author:

Zhu Min¹,Olson Kara²,Kirshner Jessica R.²,Khaksar Toroghi Masood¹,Yan Hong¹,Haber Lauric²,Meagher Craig²,Flink Dina M.³,Ambati Srikanth R.³,Davis John D.¹,DiCioccio A. Thomas¹,Smith Eric J.²,Retter Marc W.¹

Affiliation:

1. Department of Pharmacometrics Regeneron Pharmaceuticals, Inc. Tarrytown New York USA

2. Department of Research Regeneron Pharmaceuticals, Inc. Tarrytown New York USA

3. Department of Clinical Development Regeneron Pharmaceuticals, Inc. Tarrytown New York USA

Funder

Regeneron Pharmaceuticals

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13212

Reference25 articles.

1. The making of bispecific antibodies

2. A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys

3. Advances in targeted therapy for malignant lymphoma

4. Summary of a workshop on preclinical and translational safety assessment of CD3 bispecifics

5. NIH. U.S. National Library of Medicine; Clinicaltrials.gov.www.clinicaltrials.gov. Accessed August 10 2021.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells;Frontiers in Immunology;2024-04-04

2. Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma;Journal for ImmunoTherapy of Cancer;2024-03

3. Practical Application of Pk/TK Models: Preclinical PK/TK and Clinical Trial;Handbook of Pharmacokinetics and Toxicokinetics;2023-07-03

4. Strategies for clinical dose optimization of T cell-engaging therapies in oncology;mAbs;2023-02-23

5. Transient B-cell depletion and regulatory T-cells mediation in combination with adenovirus mediated IGF-1 prevents and reverses autoimmune diabetes in NOD mice;Autoimmunity;2022-10-13